二价人乳头瘤病毒疫苗不良事件关联的全国登记队列研究
芬兰全国回顾性登记队列研究评估11-15岁女孩接种二价HPV疫苗(HPV2)与38种选定自身免疫病及临床综合征的关联,240605名符合条件女孩中134615名(56%)接种。经Cox回归调整地理区域、出生国及9-10岁住院接触数后,整个随访期HPV2接种与任何结局风险升高均无统计学显著关联,风险比范围0.34(95%CI 0.11-1.05)至8.37(95%CI 0.85-82.54)。
要点
- 芬兰全国登记队列中11-15岁女孩HPV2接种率56%(134615/240605)。
- 调整后38种选定结局的风险比范围0.34(95%CI 0.11-1.05)至8.37(95%CI 0.85-82.54)。
- 整个随访期HPV2接种与任何选定结局风险升高均无统计学显著关联。
核心结论
- 研究未发现11-15岁女孩接种HPV疫苗后所选结局风险显著增加。
- 作者认为这些结果为反驳公众怀疑、对不良事件的恐惧及对HPV疫苗接种的可能反对提供了有效证据,有助于提高芬兰及其他地区的HPV疫苗接种覆盖率。
研究设计与样本
- 全国性回顾性登记队列研究,链接国家医院出院登记、人口信息系统和国家疫苗接种登记,使用个人身份代码。
- 纳入2013年11月至2016年12月期间11-15岁女孩,获取相关ICD-10编码的首次终生发生情况。
- 采用Cox回归,以年龄为主要时间尺度,首次疫苗接种剂量为时间依赖暴露,评估HPV2与38种选定结局的关联。
- 风险比(HR)及95%CI按暴露后时间(整个随访期、0-180天、181-365天、>365天)评估。
- 调整地理区域(6个医院区)、出生国(芬兰出生/非芬兰出生)及9至10岁住院接触数。
主要发现
- 240605名符合HPV2接种条件的女孩中,134615名(56%)接种。
- 调整后HR范围从0.34(95%CI 0.11-1.05)至8.37(95%CI 0.85-82.54)。
- 整个随访期内,HPV2接种与任何结局风险升高均无统计学显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A bivalent HPV vaccine (Cervarix®; HPV2, GlaxoSmithKline) was introduced into the Finnish national vaccination programme (NVP) in November 2013 for girls aged 11-13 years with a catch-up for 14-15 year-olds. We evaluated the association between HPV2 and selected autoimmune diseases and clinical syndromes by conducting a nation-wide retrospective register-based cohort study. METHODS: First life-time occurrences of the relevant ICD-10 codes in girls aged 11-15 years between Nov-2013 and Dec-2016 were obtained from the national hospital discharge register. Population denominators were obtained from the Population Information System and vaccination records from the National Vaccination Register. Registers were linked using unique personal identity codes. Association between HPV2 and 38 selected outcomes were studied using Cox regression, with age as the main time-scale and the first vaccination dose as the time-dependent exposure. The hazard ratios (HR) with 95%CI were assessed according to the time since exposure (entire follow-up, 0-180/181-365/>365 days). RESULTS: Of 240 605 girls eligible for HPV2 vaccination, 134 615 (56%) were vaccinated. After adjustment for geographical area (6 hospital districts), country of origin (Finnish-born/not) and number of hospital contacts from 9 through 10 years of age, HRs ranged from 0.34 (95%CI 0.11-1.05) to 8.37 (95%CI 0.85-82.54) and HPV2 vaccination was not statistically significantly associated with a higher risk of any outcome during the entire follow-up. CONCLUSIONS: This study found no significantly increased risk for the selected outcomes after the HPV vaccination in girls 11-15 years of age. These results provide valid evidence to counterbalance public scepticism, fears of adverse events and possible opposition to HPV vaccination and consequently can contribute to increase HPV vaccination coverage in Finland as well as elsewhere.
引用
- Skufca J, Ollgren J, Artama M, et al. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Vaccine. 2018. PMID: 30115524. doi:10.1016/j.vaccine.2018.06.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。